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Abstract
Background: Glioblastoma multiforme (GBM), due to its location, aggressiveness, heterogeneity and infiltrative
growth, is characterized by an exceptionally dismal clinical outcome. The small molecule SI113, recently identified
as a SGK1 inhibitor, has proven to be effective in restraining GBM growth in vitro and in vivo, showing also
encouraging results when employed in combination with other antineoplastic drugs or radiotherapy. Our aim was
to explore the pharmacological features of SI113 in GBM cells in order to elucidate the pivotal molecular pathways
affected by the drug. Such knowledge would be of invaluable help in conceiving a rational offensive toward GBM.
Methods: We employed GBM cell lines, either established or primary (neurospheres), and used a Reverse-Phase
Protein Arrays (RPPA) platform to assess the effect of SI113 upon 114 protein factors whose post-translational
modifications are associated with activation or repression of specific signal transduction cascades.
Results: SI113 strongly affected the PI3K/mTOR pathway, evoking a pro-survival autophagic response in neurospheres.
These results suggested the use of SI113 coupled, for maximum efficiency, with autophagy inhibitors. Indeed, the
association of SI113 with an autophagy inhibitor, the antimalarial drug quinacrine, induced a strong synergistic effect in
inhibiting GBM growth properties in all the cells tested, including neurospheres.
Conclusions: RPPA clearly identified the molecular pathways influenced by SI113 in GBM cells, highlighting their
vulnerability when the drug was administered in association with autophagy inhibitors, providing a strong molecular
rationale for testing SI113 in clinical trials in associative GBM therapy.
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Background
Glioblastoma Multiforme (GBM) is the deadliest tumor
of the central nervous system and, due to its location,
aggressive biological behavior and diffuse infiltrative
growth, presents disproportionately high morbidity and
mortality. The cornerstone of therapy consists of max-
imal well-tolerated surgical resection followed by radio-
therapy plus concurrent and adjuvant chemotherapy
with temozolomide (TMZ) [1]. Despite this optimized
treatment schedule, GBM is characterized by high rates
of recurrences, therefore the median patient survival
ranges from 12 to 15months, where less than 5% of
patients survive for more than 5 years after diagnosis [1].
Moreover, since GBM is characterized by diffusely
infiltrative growth and unusual ability in repairing the
therapy-induced damages, a complete eradication can be
exploited quite rarely [2], which ultimately leads to a
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high rate of recurrences characterized by increased
aggressiveness. Systemic therapy with TMZ, though with
its limitations, remains the standard of care for GBM,
but the frequent onset of chemoresistance in relapsed
GBM generates a compelling need for novel therapeutic
strategies. Of note, there is presently no valid alternative
to the aforementioned single-drug approach using TMZ
in concomitance of radiotherapy or alone in the adjuvant
treatment.
SI113, a small molecule identified by virtual screening of
a molecular library with respect to SGK1 crystal structures
[3], has proven to delay the cell cycle progression with cell
accumulation in G0-G1 and block cancer growth in pre-
clinical settings, both in vitro and in vivo [4, 5]. SGK1, a
structural and functional analogue of AKT [6], is a key
regulator in a number of patho-physiological cell func-
tions [7–9], thus the possibility to modulate its activity
can be functional in several diseases [10]. Indeed, SI113
inhibits epithelial-to-mesenchymal transition and subverts
cytoskeletal organization in human cancer cells [11] and,
specifically in GBM, potentiates the cytotoxic effects of
radiotherapy [12] as well as those of mitotic spindle
poisons [13]. In the attempt to delve into the mechanism
of action of this compound and assess the status of diverse
signal transduction pathways in GBM cell lines [14], we
initially employed a Reverse-Phase Protein Arrays (RPPA)
platform [15–17], a technology designed for multiplexed,
antibody-based relative quantification of specific cellular
proteins along with their post-translational modifications.
RPPA results outlined distinct molecular profiles between
anchorage-dependent established cell lines and patient-de-
rived neurospheres as far as pivotal cellular pathways gov-
erning cell growth and metabolism are concerned, either
at the baseline or under the effect of SI113. Furthermore,
SI113 triggered an autophagic response in GBM cells, ul-
timately leading to cytoprotective autophagy in neuro-
spheres, thus suggesting that its administration
concomitant with an inhibitor of the autophagic process
could effectively hinder GBM growth.
Methods
GBM cell lines
ADF human GBM cells [18] were a gift from Dr. W.
Malorni (Istituto Superiore di Sanità, Rome, Italy).
U373MG and T98G GBM cells were provided by Dr. C.
Leonetti (IRCCS - Regina Elena National Cancer Insti-
tute, Rome, Italy). Cell line authentication was per-
formed by short tandem repeat (STR) profiling, which
resulted in > = 70% match for 8 loci as per interrogation
of the ATCC STR profiling database. Similar to previous
reports in the literature [19], our U-373 MG matched
ATCC’s U-251 MG cell line. Cells were cultured as pre-
viously reported [13], were Mycoplasma-free and used
for a maximum of 20 passages.
GBM3-Luc anchorage-independent neurospheres are
a primary cell clone, growing in suspension, derived
from a specimen of a GBM patient operated in the
IRCCS - Regina Elena National Cancer Institute,
Rome, Italy, collected according to the current insti-
tutional ethical guidelines. GBM3-Luc have been char-
acterized as follows: a) derived from a GBM removed
in 2012, negative for MGMT promoter methylation
and wild-type for IDH1 gene; b) grow as neuro-
spheres; c) tumorigenic in mice (orthotopic growth);
d) CD133: negative; e) CD44: 40% positive; f ) CD56:
97% positive; g) engineered to stably express a lucifer-
ase reporter gene. GBM-I is another primary neuro-
sphere cell line, gift from Dr. A. Eramo (Istituto
Superiore di Sanità, Rome, Italy) [20, 21]. Both neuro-
spheres were cultured in DMEM/F12 stem cell
medium as described [20, 21].
Drugs
SI113 was synthesized as previously reported [3] and
diluted at a 50 mM concentration in DMSO. Quina-
crine (QC) (Sigma-Aldrich, St. Louis, MO) was di-
luted at a 10 mM concentration in phosphate-buffered
saline (PBS).
RPPA
For RPPA analysis, 3.5 × 103 GBM3-Luc, ADF and
U373MG cells were seeded onto 6-well microtiter plates;
then cells from three different passages were used for
biological replicates of individual experimental condi-
tions. In details, the RPPA experimental design included
two time points, i.e. 2 and 8 h, and two drug doses,
namely the concentration resulting in 30 and 50%
residual viability as measured at 48 h (see below for
details on the cell viability assay used), i.e. IC30 and
IC50, respectively. Control samples, i.e. cells treated with
a concentration of drug vehicle identical to that of
drug-treated samples, were included at each analyzed
time point.
Protein extracts as well as RPPA lysate printing and
immunostaining, were performed according protocols
established in our laboratory [17, 22]. Image analysis for
spot recognition, quantification and normalization was
carried out using ‘MicroVigene’ v5.2 software (http://
www.vigenetech.com/MicroVigene.htm) (VigeneTech
Inc). Data analysis was performed on averaged technical
and biological replicate values for each individual sample
condition by means of ‘R’ v3.5.0 (https://www.r-project.
org/) (R Foundation for Statistical Computing) and
‘RStudio’ v1.1.414 https://www.rstudio.com/ (RStudio)
using the following installed packages: base, plyr, tidy-
verse, ggsignif, FactoMineR, factoextra, RColorBrewer,
Bioconductor and shiny.
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Immunoblot analysis
In order to validate the RPPA results, cell lysates were
processed for western blot as described [23] and filters
were probed using the antibodies listed in Add-
itional file 1: Table S1. Further antibodies used through-
out the study: mouse anti-p62 (SQSTM1) MoAb
GT1478 (1:1000, BD Thermo Fisher Scientific, San José,
CA); rabbit anti-LC3 PoAb (1:1000, MBL International,
Woburn, MA); mouse anti-β-actin MoAb (1:10000, MP
Biomedicals, Aurora, OH); Rabbit anti-Nucleolin PoAb
(1:1000, Abcam, London, UK); mouse anti-GAPDH
(1:24000, Sigma Aldrich, Saint Louis, MO).
Cell viability assay
Cells were seeded in 96-well plates at a concentration of
5 × 103 cells/well and then treated with drugs at the
given concentrations. CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI) was employed
to determine the relative number of viable cells, after 48
h of treatment, by means of a GLOMAX 96 Microplate
Luminometer (Promega). Control samples were treated
with the same final concentration of drug solvent(s)
(DMSO and/or PBS).
Colony-forming assay
Anchorage-dependent GBM cells were plated at a con-
centration of 1–2 × 102 cells/well in 6-well plates. After
24 h, vehicle(s), SI113, QC or a combination of both (as
indicated) was added, and the culture was incubated for
48 h. Cells were then washed, cultured for additional 12
d and subsequently stained using a 5% crystal violet
solution in order to assess the colony number.
Neurosphere formation assay
GBM3-Luc and GBM-I cells were plated at 2.5 × 105
cells per well in stem medium with 10 ng/ml bFGF and
20 ng/ml EGF in a 6-well plate and treated with vehi-
cle(s), SI113, QC or a combination of both compounds
as indicated. Following 48 h treatment, GBM3-Luc cells
were dissociated into single cell suspension by means of
TrypLE Express (Gibco, Life Technologies), counted,
diluted at the appropriate concentration and re-seeded
in triplicate into new 6-well plates (1 × 102 cells per
well). At d 26 cells were examined by means of an
inverted microscope and neurospheres were counted on
averaged triplicates of 9 fields/well using a 4 x objective.
Neurosphere counting was blind and independently
performed by two investigators.
GBM-I cells were dissociated, diluted and reseeded
into new 6-well plates at the concentration of 5 × 102
cells/well. Since GBM-I cells grow more slowly and form
smaller neurospheres when compared with GBM3-Luc
cells, the former were all pelleted 26 d after treatment,
fixed in 2% PFA, stained with 2% crystal violet and cyto-
centrifuged on a slide.
Cytofluorimetric assays
Evaluation of autophagy was performed by staining cells
with Cyto-ID Autophagy Detection Kit (Enzo Life Sci-
ences, Farmingdale, NY) optimized for detection of
autophagy in live cells by flow cytometry [24]. Samples
were analyzed with a dual-laser FACScalibur flow
cytometer (BD Biosciences Franklin Lakes, NJ).
Statistical and data analysis
Antibodies were sub-selected based on the concordance
between the two analyzed time points. In details, data
from all drug treatment conditions were log10-trans-
formed and the Pearson’s correlation indices (‘r’) were
calculated, stratified by antibody and cell line, between
the 2 and 8 h time points. Endpoints included in subse-
quent data analyses comprised the roughly 25% display-
ing r values > 0.64 (third quartile) in at least one cell line
out of the three analyzed (Additional file 1: Table S1).
AMPK-α pS485 and AMPK-β pS108, but not AMPK-α
pT172, scored r values above the threshold criteria.
Nonetheless, we included AMPK-α pT172 since we
found correlation (r = 0.72) in GBM3-Luc cells between
AMPK-α pT172 and its functional substrate ACAC p79.
Along similar lines, we utilized 4E-BP1 pT70 and
ERK1–2 pT202-pY204, although not reaching the
threshold criteria, since they are functionally related to
key pathway targets.
Unless otherwise specified i) all experimental condi-
tions were tested in technical triplicates and experiments
performed at least three times, ii) all RPPA
point-and-line plots include individual values as well as
mean ± standard deviation (SD) and iii) all other results
are expressed as a mean ± standard error (SE). Data from
in vitro experiments were analyzed by One-way ANOVA
test followed by Tukey’s Multiple Comparisons Test
(GraphPad Prism v5). RPPA results were analyzed by a
custom ‘R’ algorithm designed to i) test the normality
assumption via Lilliefors or Shapiro-Wilk tests, ii)
perform ANOVA and Bonferroni post-hoc tests if the
data are normally distributed or iii) perform Kruskal-
Wallis followed by Wilcoxon rank sum or signed rank
tests as well as by FDR p value adjustment, in case of
non-normal data. Statistical significance is reported on
plots using the following notation: *P < 0.05, **P < 0.01,
***P < 0.001.
The assessment of synergy between two drugs was
done using the algorithm described by Fransson et al.
[25], where synergy is characterized by a Combination
Index (CI) < 0.8, while a CI between 0.8 and 1.2 indicates
an additive effect and values > 1.2 indicate an antagonis-
tic effect.
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As far as RPPA data are concerned, we opted for n = 9
(3 technical × 3 biological replicates) for each individual
experimental condition (cell line, drug concentration
and time point) in order to achieve a power of 0.8 to de-
tect a statistically significant (FDR 5%) difference in at
least 20% of the endpoints, given > 75% non-overlapping
populations. We generated custom R code based on ‘R
Shiny’ and useful for interactive visualization of RPPA
data by plots, dendrograms and heatmaps. The afore-
mentioned code can be made available upon request.
For in vitro data (normally distributed) we tested the
homogeneity of variance by Levene’s test and we found
out that most of the conditions evaluated were homo-
scedastic. Accordingly, we performed ANOVA.
Results
GBM cell lines, their sensitivity to SI113 and RPPA
analysis
Initially, we utilized three human GBM cell lines, two of
which were anchorage-dependent, i.e. ADF [18] and
U373MG [26], and one (GBM3-Luc), a cell clone iso-
lated from a GBM patient and growing in suspension as
neurospheres. In order to characterize
anchorage-dependent cells and neurospheres by their
pathway-level dependencies, we sought to use RPPA to
analyze GBM cells left untreated or treated with SI113.
To this end, we selected 114 antibodies, previously
pre-validated for use in RPPA, directed against a panel
of (phospho-) proteins and protein factors acceptably as-
sociated with activation or repression of specific signal
transduction cascades. The complete list of the RPPA
determinants analyzed is reported in Additional file 1:
Table S1.
To evaluate the effects of SI113, we performed a
dose-response assay and determined, for individual cell
lines, the IC30 and IC50 values after 48 h of SI113 treat-
ment (Table 1). In search for RPPA determinants of early
pathway alterations, cells were incubated with SI113, or
vehicle (control) for 2 and 8 h.
On the one side, and in order to study pathway activa-
tion signatures of treated versus untreated
anchorage-dependent cells and neurospheres, we
performed unsupervised mining on the entire,
pre-selected RPPA data subset. On the other side, we
compared sample groups by paired statistical tests on a
per-antibody basis.
Principal component analysis (PCA) showed that, re-
gardless of the treatment with SI113, GBM3-Luc cells
demonstrated different, distinctive signaling equilibria,
mainly characterized by key actors of cell cycle pathway
(PC1, Fig. 1a and b). Intriguingly, while RPPA expression
of anchorage-dependent cells was not dramatically af-
fected by SI113 treatment, in neurospheres the drug in-
duced sizeable changes of RPPA endpoints involved in
cell growth, proliferation and metabolism (PC2, Fig. 1a
and c).
In-depth comparison of baseline and treated samples
in anchorage-dependent cells and neurospheres con-
firmed the presence of individual, non-overlapping mo-
lecular responses to SI113, conveyed by a defined panel
of pathway players.
PI3K/mTOR axis
SI113 treatment caused a significant decrease of
mTOR pS2448 (Fig. 2a) and its downstream target
4E-BP1 (i.e. 4E-BP1 pT37–46 and 4E-BP1 pT70) in
neurospheres, but not in anchorage-dependent cells
(Fig. 2a and Additional file 2: Figure S1 respectively).
Therefore we focused also on another critical
mTORC1 target, i.e. S6 pS235–36, and found that SI113
affected its levels in all cell lines analyzed (Fig. 2a).
The effects of SI113 on mTOR pS2448 and S6
pS235–36 status were evident already at the IC30
dose. Since the phosphorylation of both factors is a
readout of the mTORC1 complex activity [6, 27], our
data suggest that SI113 targeted, either directly or in-
directly, the PI3K/mTOR axis. Of note, basal mTOR
pS2448 resulted elevated in neurospheres and lower,
and fairly comparable, in anchorage-dependent cells,
while baseline S6 pS235–236 displayed an opposite
pattern, being particularly low in neurospheres and
increased in anchorage-dependent cells. Nonetheless,
the decrease of S6 pS235–236 following SI113 treat-
ment remained appreciable in neurospheres (Fig. 2a
left, inset).
To assess the effects of SI113 on the mTORC2 com-
plex, we examined mTOR pS2481 [27] as well as AKT
pS473 [27] and SGK1 pS422 [28], the latter two being
known substrates of the mTORC2 kinase activity. In-
deed, SI113 appreciably down-regulated mTOR pS2481
in neurospheres but not in anchorage-dependent cells
(Additional file 2: Figure S1). These results were paral-
leled by a significant reduction of AKT pS473 and SGK1
pS422 after treatment with the lowest dose of SI113 in
GBM3-Luc cells only (Fig. 2b, left).
Table 1 IC 30 and IC50 values for SI113 in ADF, U373MG and
T98G human GBM anchorage-dependent cell lines and for
GBM3-Luc and GBM-I neurospheres
Cell line IC30 for SI113 (μM) IC50 for SI113 (μM)
ADF 10.4 19.7
U373MG 7.0 14.45
T98G 5.23 6.65
GBM3-Luc 9.47 19.15
GBM-I 9.10 17.21
Values were determined by titrating the effect of the drug in a cell viability
assay after 48 h of treatment. The data reported are the average of two
different experiments performed in triplicate
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In order to achieve a full comprehension of
SI113-mediated changes in the PI3K/mTOR pathway,
we selected two key readouts, i.e. MDM2 and NDRG1
[6], which are phosphorylated by AKT and SGK1 in
serine 166 [29, 30] and 330 [31–33], respectively. In the
presence of SI113, both factors resulted considerably
hypo-phosphorylated in neurospheres. Vice versa, in
anchorage-dependent cells only the highest dose of
SI113 caused a significant decrease of MDM2 pS166
and only one out of the two anchorage-dependent
cells analyzed underwent a reduction in NDRG1
pS330 at SI113 IC30 (Fig. 2c, left). Interestingly,
RPPA levels of FOXO1 pS256 and FOXO1
pT24-FOXO3a pT32 were selectively affected by
SI113 in neurospheres mirroring, in such cells, the
drug-induced decline of AKT phosphorylation and, to
a lesser extent, that of SGK1, being both AKT and
SGK1 upstream regulators of FOXOs’ activity (Add-
itional file 2: Figure S1) [34–37].
Apoptosis
SI113 has been shown to trigger apoptosis in cultured
cancer cells [4, 5]. Thus we measured the amount of
cleaved PARP (PARP D214) [38] after treatment with
SI113. Apparently, PARP D214 displayed a sizeable,
significant SI113-dependent reduction mainly in neuro-
spheres (Fig. 2d, left).
Altogether, the RPPA output obtained after exposure
of GBM cells to SI113 showed i) an overall reduction of
mTORC1 activity paralleled by ii) a neurosphere-select-
ive mTORC2 down-modulation accompanied by iii) a
remarkable decrease in AKT pS473 and SGK1 pS422,
mostly in neurospheres, and iv) a reduction of
apoptosis-related endpoints. These results suggest that
Fig. 1 Principal Component Analysis (PCA) of RPPA data. The subset of antibodies selected after thresholding the correlation indices between
different time points, was used for PCA on the correlation matrix of data at a single time point (8 h). The bi-plot in (a) shows the scores of
analyzed samples, i.e. cell lines and SI113 levels, annotated by the color and the size of the symbols, respectively. The relative weight of individual
endpoints (loadings) is overlaid and highlighted by arrows. Histograms in (b) and (c) show the relative contribution of endpoints (expressed as
percentage of the contribution of all variables) with significantly high correlations in the first and the second PC, respectively. The red, dashed
line indicates the threshold level of relative contribution
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neurospheres, under the effect of SI113, might co-opt
for a survival-oriented autophagic process.
Autophagy
Intrigued by the above results, we investigated RPPA
endpoints involved in the autophagy pathway. Indeed,
the neurosphere-specific inhibition of mTOR pS2448 by
SI113 was mirrored by a drug-induced increase in
phosphorylation of the energy sensor AMPK-α (at threo-
nine 172) (AMPK-α pT172 a.k.a. AMPK-α pT183) and
its substrate ACACA pS79 (a.k.a. ACACA pS80), two
specific readouts of the onset of an autophagic process
[39, 40] (Fig. 2e, left). Indeed, while AMPK-α phosphor-
ylation correlates with a raise in its kinase activity,
AMPK-α-mediated phosphorylation of ACACA at S79
results in inactivation of the ACACA enzyme activity.
Therefore, we hypothesized that triggering of an autoph-
agic process would result in a raise of NADPH levels
with concomitant down-modulation of fatty-acid synthe-
sis and increased rates of fatty-acid oxidation [41, 42].
All the RPPA results were validated by western blotting
(Fig. 2a, b, c, d and e, right).
In line with such a molecular scenario, we found a
neurosphere-specific down-regulation of fatty-acid synthase
Fig. 2 RPPA analysis of mTORC1 and mTORC2 activity. GBM3-Luc,
ADF and U373MG cells were incubated in the absence or in the
presence of SI113 and then processed for RPPA and Western blot
(left and right panels, respectively). SI113 was employed at the IC30
and IC50 concentrations specific for each cell line. Unless otherwise
specified all RPPA plots refer to results obtained at 8 h of exposure
to SI113. When significant, statistical comparisons (Wilcoxon signed-
rank test, FDR-adjusted p values) are reported on each individual
plot. Statistical significance coding is described in the Materials and
Methods section of the manuscript. a. mTORC1. RPPA plots
represent the trend of mTOR pS2448 and S6 pS235–36
phosphorylation as readouts of mTORC1 activation status. mTOR
pS2448 and S6 pS235–36 normalization was performed by GAPDH
quantification. b. mTORC2. Representative RPPA plots of SGK1 pS422
(2 h time point shown) and AKT pS473 show the trend of mTORC2
activity upon treatment with SI113. SGK1 pS422 was normalized
against the GAPDH determination previously used for mTOR pS2448,
while AKT pS473 in U373MG cells shares the loading control
(GAPDH) with S6 pS235–36. c. AKT and SGK1 activity. RPPA plots
represent the phosphorylation trend of MDM2 and NDRG1, which
are targets of the AKT/SGK1 activity, under the effect of SI113.
Nucleolin content was used for MDM2 pS166 normalization while
GAPDH, the same as the one reported for SGK1 pS422 normalization
in panel B, was used for NDRG1 pS330 normalization. d. Apoptosis.
RPPA plots display the trend of cleaved PARP (D214) after SI113
treatment. GAPDH determination used for PARP D214 normalization
in GBM3-Luc and ADF cells was done on the same filter used for
AKT pS473. e. Autophagy. Plots of ACACA pS79 and AMPK-α pT172
RPPA levels are shown here to represent the trend of the
autophagic process under the effect of SI113. ACACA pS79 in
U373MG cells share the same GAPDH normalization used for AKT
pS473 and S6 pS235–236. AMPK-α pT172 in GBM3-Luc and ADF cells
share the same GAPDH normalization used for S6 pS235–236.kDa =
apparent molecular mass
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(FASN) after SI113 treatment (Additional file 2: Figure S1),
indicating the selective stimulation of an energy-saving,
pro-survival autophagic process in neurospheres.
Interestingly, mTOR pS2448 and ACACA pS79
showed significant SI113-mediated changes and these
molecular readouts of autophagy were found
pronounced in neurospheres as compared to
anchorage-dependent cells. Indeed, although SI113
inhibited ACACA pS79 in a dose-dependent manner in
all analyzed cell lines, in GBM3-Luc cells the drug se-
lectively induced a concomitant increase of AMPK-α
pT172 and decrease of mTOR pS2448. Moreover, des-
pite a SI113-induced decline in Cyclin B1 in all analyzed
cell lines, the levels of phosphorylated ERKs (ERK1–2
pT202-pY204) underwent significant reduction in neu-
rospheres only (Additional file 2: Figure S1). Therefore,
it could be argued that these cells halted their prolifera-
tion state and, differently from anchorage-dependent
lines, were able to mount an autophagic response. In
line with such a hypothesis, we found that neurospheres
and anchorage-dependent cells displayed differential
ground level phosphorylation of S6 pS235–236, a bona
fide readout of the autophagy regulator mTORC1 [43].
Altogether, our RPPA data suggest, as previously dem-
onstrated in other model systems [12, 13], that SI113
elicited an autophagic response in GBM cells particularly
evident in neurospheres and arguably associated with a
pro-survival, autophagic strategy utilized to endure the
treatment with SI113.
The raw data concerning the RPPA platform output
are listed in Additional file 3: Table S2.
Synergy between SI113 and the antimalarial drug
quinacrine in restraining GBM cell growth
Recently, antimalarial drugs belonging to the 4-amino
quinoline class have been demonstrated to inhibit
autophagy at its late stages [44] contributing to hamper
cancer cell growth, mainly in the subset of
tumor-initiating cells [45–48]. We therefore employed in
our experimental setting the quinolone derivative quina-
crine (QC) [49], due to its highest activity in inhibiting
autophagy in glioma cells and ability to cross the
Blood-Brain Barrier [44]. Thus, the effect of SI113 and
QC, as well as that of their combined administration,
was assayed in GBM cells, where QC was envisaged to
impair the autophagic survival process elicited by SI113.
Sensitivity to QC was assessed for the GBM cell lines
ADF, U373MG and GBM3-Luc neurospheres. We also
assayed the T98G anchorage-dependent GBM cell line
[32] and the GBM-I neurospheres [20, 21]. IC50 values
for QC are reported in Table 2. All these cells appeared
susceptible to QC in the low micro-molar range, thus
confirming the ability of quinoline-derived compounds
to hinder per se GBM growth [50–52].
Cell viability assay
To highlight a potential synergistic effect between the
two drugs, SI113 was employed at a fixed concentration,
varying among the different cell lines according to their
susceptibility to the drug, as follows: 8.5 μM for ADF;
7.9 μM for U373MG; 4.5 μM for T98G; 4 μM for
GBM3-Luc and 6.5 μM for GBM-I. To assay for a syner-
gistic effect, increasing doses of QC were then employed,
ranging from 0.078 to 20 μM. Cell viability was assessed
after 48 h. By using the algorithm described by Fransson
et al. [25], we analyzed the outcome of the drug combin-
ation compared with that of the compounds used as
single agents (Fig. 3a, b, c, d and e, left). Indeed, the
addition of QC to SI113 yielded a decrease in cell viabil-
ity definitely attributable to a synergistic effect of the
two drugs within an extended range of QC concentra-
tions for all the cell lines. (Fig. 3a, b, c, d and e, right).
Clonogenic assays
In this setup, drug doses were modified as indicated in
Fig. 4.
Colony-forming assay ADF, U373MG and T98G cells
were exposed to the drug(s) or their respective solvent(s)
and the effect of the treatment was evaluated via the
inhibition of the number of cell colony formation. For
all these cell lines, cloning efficiency was dramatically
reduced when SI113 and QC were used in combination
(Fig. 4a, b and c, pictures on the left and histograms on
the right).
Neurosphere formation assay In the case of GBM3-Luc
neurospheres we adopted a different technique. As shown
in Fig. 4d (pictures on the left and histograms on the
right), a potentiation of the effects between SI113 and QC
in restraining neurosphere formation was clearly evident
also in this cell line. Statistical significances for each panel
of Fig. 4 are reported in the Figure legend. Growth and
morphological characteristics of the GBM-I neurospheres
did not allow a reliable count of the colonies in dishes; in
this case, cells needed to be cytocentifuged after the
Table 2 IC50 values for QC in ADF, U373MG and T98G human
GBM anchorage-dependent cell lines and for GBM3-Luc and
GBM-I neurospheres
Cell line IC50 for QC (μM)
ADF 2.46
U373MG 2.39
T98G 2.18
GBM3-Luc 4.79
GBM-I 5.43
Values were determined by titrating the effect of the drug in a cell viability
assay after 48 h of treatment. The data reported are the average of two
different experiments performed in triplicate
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treatments. In GBM-I cells, the growth restraining effect
of SI113 and QC was evident when administered in
combination, while SI113 alone appeared to stimulate the
formation of colonies (Additional file 4: Figure S2).
Analysis of the autophagic process in GBM cells after
exposure to SI113 and/or QC
For a precise analysis of the autophagic processes, the
specific determinants LC3-I/LC3-II and p62 [53] were
assayed by western blot after exposure to SI113 and/or
QC at the doses indicated above in the clonogenic assay
for 48 h and compared to controls.
All three anchorage-dependent GBM cell lines, after
exposure to SI113, underwent an increase in the amount
of both LC3 II and p62, possibly related to a block of
the autophagic flux or induction of cytotoxic autophagy
[53]. As expected, the autophagy blocker QC induced an
increase in the amount of p62 in U373MG and T98G
Fig. 3 Cell Viability Assay. Dose-response effects of SI113 (green), QC (blue) and QC plus a constant (k) SI113 concentration (red) on percent cell
viability (left panels) and histograms showing cell viability at selected drug concentrations, as indicated, to highlight the effect of the association
of the two drugs (right panels). The effects of QC and SI113 combination drugs were considered synergistic when the CI was < 0.8 (in red). SI113
k values were 8.5, 7.9, 4.5, 4 and 6.5 μM for ADF (a), U373MG (b), T98G (c), GBM3-Luc (d) and GBM-I cells (e), respectively
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cells, which was not the case in ADF cells. When SI113
and QC were administered together, there was a further
increase in the amount of p62 in all the three cell lines.
When autophagy was analyzed in neurospheres,
GBM3-Luc cells showed, in the presence of SI113, a
relative increase in the LC3 II band, while in GBM-I
cells a visible increase was apparent along with a de-
crease in the amount of LC3 I. Under the same con-
ditions, a decrease in the amount of p62 was
appreciable under the effect of SI113. These scenar-
ios are all compatible with an increased autophagic
rate [53]. In the presence of QC, a noticeable block
of the autophagic process was evident in both cell
lines, as assumed by the coupled increase of LC3 II
and p62 [53]. Interestingly, where the cytotoxic
effects of the association of SI113 with QC was
more evident, a dramatic increase in LC3 II was
observed in concomitance with an increase of p62. A
noticeable decrease in β-actin amount, here used as
a loading control, was also apparent, a phenomenon
attributed to intracellular degradation events associ-
ated with cell death.
Semi-quantitative assessment of LC3 II and p62
amounts, normalized against the β-actin content, is
reported for each cell line (Fig. 5a, b, c, d and e).
These results were also validated by flow cytometry
using the CYTO-ID autophagy detection kit
(Table 3).
Fig. 4 Clonogenic Assay. a. ADF cells were exposed to solvent(s) (Control), 8.5 μM SI113, 0.5 μM QC or their association for 48 h and then allowed
to grow and form colonies for the subsequent 12 d. Cell colonies, after staining with crystal violet (left), were counted and the values reported as
percent colony number in the histogram (right). b. U373MG cells treated as in panel a, except for the use of SI113 at a concentration of 4.5 μM.
c. T98G cells treated as in panel b, except for the use of QC at a concentration of 1 μM. d. GBM3-Luc cells were exposed to solvent(s) (Control),
4 μM SI113, 1 μM QC or their association for 48 h and then allowed to grow and form colonies for the subsequent 26 d. Cell colonies were
observed and photographed in phase contrast microscopy (left), counted and the values reported as percent colony number in the histogram
(right). In these panels, statistical analysis among groups was done using the One-way ANOVA test followed by the Tukey’s Multiple Comparison
Test (* significance vs. Control; ^ significance vs. SI113; § significance vs. QC)
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Discussion
The small molecule SI113 was originally identified as an
inhibitor of the SGK1 kinase activity and the role of the
drug in this context has been documented satisfactorily
[4, 5, 12, 13]. SGK1 plays a key functional role in the
PI3K/mTOR pathway and is able to sustain
AKT-independent mTORC1 activation [6].
The strong impact of SI113 on cancer cell survival has
been highlighted by several previous studies. Nonethe-
less, here we aimed at exploring in depth the pharmaco-
logical capability of SI113 in interfering with major
signal transduction pathways in GBM cells. Indeed,
SI113 was effective in hindering proliferation and clon-
ing efficiency in anchorage-dependent GBM cell lines
and neurospheres.
RPPA revealed a peculiar role of SI113 in GBM3-Luc
neurospheres, where it provoked a rapid (already at 2 h
and IC30) reduction of cell cycle related endpoints, i.e.
Cyclin B1 and phospho-ERKs, and promoted a
survival-oriented autophagic process. Indeed, upon treat-
ment with SI113, a series of key pathway players, includ-
ing mTOR pS2448 and its downstream targets 4E-BP1
pT37–46 and S6 pS235–236, as well as AMPK-α pT172
and ACACA pS79, displayed a striking correlation
selectively in neurospheres. Concordantly, treatment
with SI113 caused a decrease in cleaved PARP D214 in
GBM3-Luc cells, thus excluding the involvement of an
apoptotic process in these cells. In line with these data,
analysis of the expression of LC3 and p62 showed that
both GBM-3 Luc and GBM-I neurospheres underwent
autophagy when exposed to SI113.
It should be remarked that GBM is characterized by
the concomitance of diverse pathway alterations includ-
ing, but not limited to, RTKs, PI3K/mTOR, Ras/MAPKs
and cell cycle [54]. In this regard, it is widely accepted
that mTOR inhibition leads to ERK activation in a
PI3K-dependent manner [55] and that receptor tyrosine
kinase-driven signals are rewired accordingly to selective
blockade of either PI3K/mTOR or Ras/MAPK axes [56,
57]. These acquired notions pose the rationale for de-
signing combination therapies involving concomitant
targeting of PI3K and MAPKs [58]. Interestingly, SI113
was capable of targeting neurospheres by inhibition not
only of PI3K/mTOR pathway but also of the MAPKs
cascade, as represented by the noticeable drop in the
levels of ERK1–2 phosphorylation in SI113-exposed
GBM3-Luc cells (Additional file 4: Figure S2). Such a
scenario implies that, for a minimally effective inhibition
of GBM cell growth, both the aforementioned pathways
should be targeted [59]. Once again, SI113 is a very
interesting candidate compound for GBM therapy, being
capable of hindering multiple pathways and thus expos-
ing GBM3-Luc neurospheres vulnerabilities.
Additionally, the autophagy inhibitor QC, which, as
expected [50–52], displayed considerable toxicity
towards all the GBM cell lines tested (see Table 1) show-
ing also an unquestionable ability to cooperate with
SI113 in hindering GBM cells growth capabilities. In-
deed, we found a strong synergy between SI113 and QC
in contrasting key features of both anchorage-dependent
GBM cells and neurospheres. Since the latter ones are
usually resistant to standard anticancer treatments and
display cancer stem cells behaviors, our results hold a
substantial clinical significance.
Recently, ferroptosis, a peculiar form of cell death
occurring through Fe (II)-dependent lipid peroxidation,
has been shown to play a major role in cancer cell
Fig. 5 Analysis of the autophagic process. ADF, U373MG, T98G, GBM3-Luc and GBM-I (Panels a to e) GBM cells were incubated with SI113, QC or
their combination using the drug doses employed in Fig. 4 for 48 h and then assayed via western blot for LC3 and p62, as determinants of the
autophagic process. Semi-quantitative assessment of LC3 II and p62 amounts, normalized against the β-actin content, is reported for each cell
line. kDa = apparent molecular mass
Table 3 Cytofluorimetric determination of autophagy in GBM
cells exposed to SI113 and/or QC
Cell Line Control SI113 QC SI113 + QC
ADF 60.3 ± 4.2 68.9 ± 4.7 82.3 ± 7.2 99.7 ± 7.1
U373MG 75.4 ± 7.7 82.7 ± 5.4 87.6 ± 5.7 95.4 ± 6.5
T98G 73.3 ± 6.5 92.7 ± 4.4 86.5 ± 4.1 95.4 ± 9.3
GBM3-Luc 59.4 ± 5.6 64.5 ± 5.4 71.9 ± 5.1 94.6 ± 6.7
GBM-I 20.9 ± 2.2 25.8 ± 2.5 28.5 ± 2.1 36.8 ± 2.9
Cytofluorimetric assay for autophagy (see Materials and Methods) in GBM cell
lines that were exposed to the drugs as specified in Fig. 4. Autophagic process
was quantified by analyzing the median fluorescence intensity values and is
expressed as Arbitrary Units
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apoptotic processes [60]. In addition, it has been re-
ported that the blockade of autophagy by means of QC
can enhance sensitivity to TMZ in GBM neurospheres
by igniting ferroptosis [61].
In summary, autophagy allows GBM cells to survive
in a hostile environment and is regarded as a cyto-
protective adaptive reaction, particularly in cancer
stem cells [62–64]. Herein, exposure to SI113 forced
neurosphere cells towards a pro-survival autophagic
response that was efficiently constrained by the au-
tophagy inhibitor QC, thus provoking the suppression
of a survival pathway that these cells likely depend
on. Therefore, we envisage a combination therapy ap-
proach that, differently from standard “one-hit” tar-
geted therapies, could be based on synthetic lethality,
inhibiting primitive cancer cell survival pathways, be-
ing thus less prone to the emergence of resistant
clones and providing strong benefits in a foreseen
clinical setting. Indeed, GBM due to its heterogeneity
cannot be considered as a “single pathway disease”
and doesn’t represent the best environment to assay
the effects of a targeted therapy. Conversely, in this
disease there is a window of opportunity for the
so-called dirty drugs that, far from being specific, can
take advantage of selective vulnerabilities of GBM
cells, e.g. dependence from aberrant energy supply
pathways or pro-survival autophagic response to hos-
tile environment. In such a scenario, our results show
the importance to have a complete signal transduc-
tion portrait in order to address the most efficient
therapeutic strategies.
Conclusions
All so far published in vitro and in vivo preclinical stud-
ies based on SI113 hold great promises for its use in a
combinatorial therapeutic regimen in cancer, including
GBM [4, 12]. In this respect, a novel therapeutic strategy
consisting in TMZ plus SI113 and QC, may provide an
effective drug cocktail against GBM [14]. Notably, SI113
has been demonstrated to potentiate the effects of radio-
therapy in GBM cells [12], thus advocating its clinical
use in GBM. Furthermore, QC or other quinolone deriv-
atives, e.g. the widely used chloroquine, display
well-established levels of toxicity and dosage in humans,
making them ideal candidates for drug repositioning
[14].
Therefore, all the aforementioned elements converge
in supporting a Phase 1 clinical trial for safety and dos-
age assessment of SI113 and QC or its analogs, in order
to evaluate the effects of their co-administration with
TMZ (and, when still possible, radiation therapy) in
GBM patients who have exhausted all available treat-
ment options.
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